🇪🇺 Secukinumab Auto-Injector in European Union

EMA authorised Secukinumab Auto-Injector on 14 January 2015

Marketing authorisation

EMA — authorised 14 January 2015

  • Application: EMEA/H/C/003729
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Cosentyx
  • Indication: Plaque psoriasis Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. Hidradenitis suppurativa (HS) Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. Psoriatic arthritis Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease mo
  • Status: approved

Read official source →

Other Immunology approved in European Union

Frequently asked questions

Is Secukinumab Auto-Injector approved in European Union?

Yes. EMA authorised it on 14 January 2015.

Who is the marketing authorisation holder for Secukinumab Auto-Injector in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.